Marcus A. Mall spends much of his time researching Cystic fibrosis, Cystic fibrosis transmembrane conductance regulator, Internal medicine, Endocrinology and Immunology. His work deals with themes such as Pathogenesis, Epithelial sodium channel, Magnetic resonance imaging, Radiology and Lung, which intersect with Cystic fibrosis. His Lung study combines topics in areas such as Chronic bronchitis and Pathology.
His study looks at the relationship between Cystic fibrosis transmembrane conductance regulator and fields such as Mutation, as well as how they intersect with chemical problems. Marcus A. Mall focuses mostly in the field of Internal medicine, narrowing it down to topics relating to Chloride channel and, in certain cases, Cancer research. His study looks at the relationship between Immunology and topics such as Glycoprotein, which overlap with Epitope, Asymptomatic, Respiratory failure and Cell culture.
Marcus A. Mall mainly investigates Cystic fibrosis, Pathology, Immunology, Lung and Cystic fibrosis transmembrane conductance regulator. His Cystic fibrosis research is within the category of Internal medicine. He interconnects Neutrophil elastase, COPD and In vivo in the investigation of issues within Pathology.
His Immunology study integrates concerns from other disciplines, such as Airway and Mucociliary clearance. His Lung research incorporates elements of Epithelium and Obstructive lung disease. His studies deal with areas such as Cancer research, Molecular biology, Ion channel, Cell biology and Pharmacology as well as Cystic fibrosis transmembrane conductance regulator.
Cystic fibrosis, Immunology, Lung, Inflammation and Pathology are his primary areas of study. His Cystic fibrosis study introduces a deeper knowledge of Internal medicine. The various areas that he examines in his Internal medicine study include Gastroenterology, Endocrinology and Epithelial sodium channel.
Marcus A. Mall combines subjects such as Cftr modulator and Glycoprotein with his study of Immunology. His Lung study incorporates themes from In vivo, Obstructive lung disease and Pathogenesis. In his study, In vitro, Edema and Mutation is strongly linked to Function, which falls under the umbrella field of Pathology.
His primary areas of investigation include Cystic fibrosis, Immunology, Inflammation, Pathology and Ivacaftor. He is interested in Cystic fibrosis transmembrane conductance regulator, which is a field of Cystic fibrosis. His Cystic fibrosis transmembrane conductance regulator research integrates issues from Homeostasis, Mucociliary clearance, Epithelial sodium channel and Pharmacology.
In his work, Cell culture, Respiratory failure, Asymptomatic and Epitope is strongly intertwined with Glycoprotein, which is a subfield of Immunology. His work focuses on many connections between Inflammation and other disciplines, such as Disease, that overlap with his field of interest in Lung injury and Phagocytosis. As a member of one scientific family, he mostly works in the field of Pathology, focusing on Interstitial lung disease and, on occasion, Fibrosis and Pulmonary fibrosis.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Increased airway epithelial Na+ absorption produces cystic fibrosis-like lung disease in mice.
Marcus Mall;Barbara R Grubb;Jack R Harkema;Wanda K O'Neal.
Nature Medicine (2004)
Electrolyte Transport in the Mammalian Colon: Mechanisms and Implications for Disease
Karl Kunzelmann;Marcus Mall.
Physiological Reviews (2002)
SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19.
Julian Braun;Lucie Loyal;Marco Frentsch;Daniel Wendisch.
Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele
Peter G Middleton;Marcus A Mall;Pavel Dřevínek;Larry C Lands.
The New England Journal of Medicine (2019)
Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation : a double-blind, randomised, phase 3 trial
Harry G M Heijerman;Edward F McKone;Damian G Downey;Eva Van Braeckel.
The Lancet (2019)
Characterization of Wild-Type and ΔF508 Cystic Fibrosis Transmembrane Regulator in Human Respiratory Epithelia
Silvia M. Kreda;Marcus Mall;April Mengos;Lori Rochelle.
Molecular Biology of the Cell (2005)
VX-445-Tezacaftor-Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles.
Dominic Keating;Gautham Marigowda;Lucy Burr;Cori Daines.
The New England Journal of Medicine (2018)
CXCR2 mediates NADPH oxidase–independent neutrophil extracellular trap formation in cystic fibrosis airway inflammation
Veronica Marcos;Zhe Zhou;Ali Önder Yildirim;Alexander Bohla.
Nature Medicine (2010)
Innate immunity in cystic fibrosis lung disease
D. Hartl;A. Gaggar;E. Bruscia;A. Hector.
Journal of Cystic Fibrosis (2012)
Role of Cilia, Mucus, and Airway Surface Liquid in Mucociliary Dysfunction: Lessons from Mouse Models
Marcus A. Mall.
Journal of Aerosol Medicine and Pulmonary Drug Delivery (2008)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: